StockData

Universe Pharmaceuticals vs Viatris

UPC and VTRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How UPC and VTRS compare

Viatris grew revenue faster over the last twelve months (4.3% versus −22.4% for Universe Pharmaceuticals).

Viatris pays a dividend yielding 2.3%; Universe Pharmaceuticals does not pay one.

Viatris scores higher on the StockData Score (6 against 5 for Universe Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricUPCVTRS
Size and price
Market cap–$23.9B
Share price$1.51$20.82
Change, 1 year−59.0%89.1%
Change, 5 years−100.0%59.2%
Beta (5Y)1.060.86
Employees22530K
StockData Score
Total score56 (better)
Valuation score02 (better)
Growth score2 (better)1
Performance score1 (better)0
Health score2 (better)1
Dividend score02 (better)
Valuation
P/S–1.6×
EV/EBITDA–12.6×
P/FCF–11.3×
FCF yield–8.8%
Fair value–$23.22
Margin of safety–10.4%
Growth
Revenue growth (TTM)−22.4%4.3% (better)
Revenue growth, 5Y average257% (better)3.7%
Profitability
Gross margin35.3%35.3% (better)
Operating margin−16.3%−0.03% (better)
Net margin−20.6%–
FCF margin−29.8%14.3% (better)
Return on equity−7261%–
Return on invested capital−78.0%–
Financial health
Debt / equity0.13–
Net debt / EBITDA–4.10
Interest coverage−10.1×−0.0× (better)
Current ratio4.05 (better)1.55
Altman Z-score–1.21
Piotroski F-score4–
Dividends and buybacks
Dividend yield–2.3%
Years of dividend growth–0
Buyback yield–1.6%
Shareholder yield–3.9%
Ownership
Held by institutions6.6%91.5%
Held by insiders–0.36%
Insider net buying, 12 months–−$1.1M
Superinvestors holding–3
Short interest, % of float–3.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.